Folate-related birth defects: Embryonic consequences of abnormal folate transport and metabolism

Folate in Health and Disease, Second Edition

Volumn , Issue , 2009, Pages 155-178

  Wallis, Deeann ^a   Ballard, Johnathan L ^b   Shaw, Gary M ^c   Lammer, Edward J ^d   Finnell, Richard H ^b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c STANFORD UNIVERSITY   (United States)

^d CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649867126     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (125)

1. Christianson A, Howson CP, Modell B. March of Dimes Global Report on Birth Defects. White Plains, NY: March of Dimes Research Foundation, 2006.
2. Yoon PW, Olney RS, Khoury MJ, Sappenfield WM, Chavez GF, Taylor D. Contribution of birth defects and genetic diseases to pediatric hospitalizations. A population-based study. Arch Pediatr Adolesc Med 1997; 151:1096-103.
3. Waitzman NJ, Romano PS, Scheffler RM. Estimates of the economic costs of birth defects. Inquiry 1994; 31:188-205.
4. Martin JA, Kochanek KD, Strobino DM, Guyer B, MacGillivray I. Annual summary of vital statistics—2003. Pediatrics 2005; 115:619-34.
5. Scherson T, Serbedzija G, Fraser S, Bronner-Fraser M. Regulative capacity of the cranial neural tube to form neural crest. Development 1993; 118:1049-62.
6. Noden DM. An analysis of migratory behavior of avian cephalic neural crest cells. Dev Biol 1975; 42:106-30.
7. Noden DM. The control of avian cephalic neural crest cytodifferentiation. I. Skeletal and connective tissues. Dev Biol 1978; 67:296-312.
8. Noden DM. The control of avian cephalic neural crest cytodifferentiation. II. Neural tissues. Dev Biol 1978; 67:313-29.
9. Noden DM. The embryonic origins of avian cephalic and cervical muscles and associated connective tissues. Am J Anat 1983; 168:257-76.
10. Maschhoff KL, Baldwin HS. Molecular determinants of neural crest migration. Am J Med Genet 2000; 97:280-88.
11. Piedrahita JA, Oetama B, Bennett GD, van Waes J, Kamen BA, Richardson J, Lacey SW, Anderson RG, Finnell RH. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet 1999; 23:228-32.
12. Barber RC, Bennett GD, Greer KA, Finnell RH. Expression patterns of folate binding proteins one and two in the developing mouse embryo. Mol Genet Metab 1999; 66:31-39.
13. Saitsu H, Ishibashi M, Nakano H, Shiota K. Spatial and temporal expression of folatebinding protein 1 (Fbp1) is closely associated with anterior neural tube closure in mice. Dev Dyn 2003; 226:112-17.
14. Shaw GM, O’Malley CD, Wasserman CR, Tolarova MM, Lammer EJ. Maternal peri-conceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 1995; 59:536-45.
15. Tang LS, Finnell RH. Neural and orofacial defects in Folp1 knockout mice [corrected]. Birth Defects Res A Clin Mol Teratol 2003; 67:209-18.
16. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: Clinical consequences. Am J Pharmacogenomics 2001; 1:189-201.
17. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19:217-46.
18. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci2004; 61:470-87.
19. Jakubowski H. Homocysteine thiolactone: Metabolic origin and protein homocysteiny-lation in humans. J Nutr 2000; 130:377S-81S.
20. Perna AF, Satta E, Acanfora F, Lombardi C, Ingrosso D, De Santo NG. Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int 2006; 69:869-76.
21. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98:5-7.
22. Nelson MM. Teratogenic effects of pteroylglutamic acid deficiency in the rat. Ciba Foundation Symp Cong Malfs 1960:134-57.
23. Nelson MM, Baird CD, Wright HV, Evans HM. Multiple congenital abnormalities in the rat resulting from riboflavin deficiency induced by the antimetabolite galactoflavin. J Nutr 1956; 58:125-34.
24. Warkany J, Nelson RC. Appearance of skeletal abnormalities in the offspring of rats reared on a deficient diet. Science 1940; 92:383-84.
25. Natsume N, Nagatsu Y, Kawai T. Direct effect of vitamins at the time of palatal fusion. Plast Reconstr Surg 1998; 102:2512-13.
26. Spiegelstein O, Mitchell LE, Merriweather MY, Wicker NJ, Zhang Q, Lammer EJ, Finnell RH. Embryonic development of folate binding protein-1 (Folbpl) knockout mice: Effects of the chemical form, dose, and timing of maternal folate supplementation. Dev Dyn 2004; 231:221-31.
27. Tang LS, Wlodarczyk BJ, Santillano DR, Miranda RC, Finnell RH. Developmental consequences of abnormal folate transport during murine heart morphogenesis. Birth Defects Res A Clin Mol Teratol 2004; 70:449-58.
28. Finnell RH, Spiegelstein O, Wlodarczyk B, Triplett A, Pogribny IP, Melnyk S, James JS. DNA methylation in Folbp1 knockout mice supplemented with folic acid during gestation. JNutr 2002; 132:2457S-61S.
29. Gelineau-van Waes J, Heller S, Bauer LK, Wilberding J, Maddox JR, Aleman F, Rosenquist TH, Finnell RH. Embryonic development in the reduced folate carrier knockout mouse is modulated by maternal folate supplementation. Birth Defects Res A Clin Mol Teratol2008; 82:494-507.
30. Choi SW, Mason JB. Folate status: Effects on pathways of colorectal carcinogenesis. J Nutr2002; 132:2413S-18S.
31. McKay JA, Williams EA, Mathers JC. Folate and DNA methylation during in utero development and aging. Biochem Soc Trans 2004; 32:1006-07.
32. MRC Vitamin Study Research Group. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-37.
33. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by peri-conceptional vitamin supplementation. N Engl J Med 1992; 327:1832-35.
34. Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H, Molloy AM, Weir DG, Shields DC, Scott JM. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. QJM 1995; 88:763-66.
35. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, Scott JM. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995; 345:149-51.
36. Verkleij-Hagoort AC, Verlinde M, Ursem NT, Lindemans J, Helbing WA, Ottenkamp J, Siebel FM, et al. Maternal hyperhomocysteinaemia is a risk factor for congenital heart disease. BJOG 2006; 113:1412-18.
37. Verkleij-Hagoort A, Bliek J, Sayed-Tabatabaei F, Ursem N, Steegers E, Steegers-Theunissen R. Hyperhomocysteinemia and MTHFR polymorphisms in association with orofacial clefts and congenital heart defects: A meta-analysis. Am J Med Genet A 2007; 143:952-60.
38. Friso S, Choi SW. Gene-nutrient interactions and DNA methylation. J Nutr 2002; 132:2382S-87S.
39. Jordan RL, Wilson JG, Schumacher HJ. Embryotoxicity of the folate antagonist methotrexate in rats and rabbits. Teratology 1977; 15:73-79.
40. Peer LA, Strean LP. Stress as an etiologic factor in the development of cleft palate. Plast Reconstr Surg 1956; 18:1-8.
41. Hernandez-Diaz S, Werler MM, Walker AH, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608-14.
42. Anderson RC. Cardiac defects in children of mothers receiving anticonvulsant therapy during pregnancy. J Pediatr 1976; 89:318-19.
43. Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. Anticonvulsants, folate levels, and pregnancy outcome: A prospective study. Ann Neurol 1987; 21:176-82.
44. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 2: Human studies. Reprod Toxicol 1991; 5:301-35.
45. Wegner C, Nau H. Diurnal variation of folate concentrations in mouse embryo and plasma: The protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent. Reprod Toxicol 1991; 5:465-71.
46. Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis. Neurology 1992; 42:17-24.
47. Hill L, Murphy M, McDowall M, Paul AH. Maternal drug histories and congenital malformations: Limb reduction defects and oral clefts. J Epidemiol Community Health1988; 42:1-7.
48. Shaw GM, Wasserman CR, O’Malley CD, Lammer EJ, Finnell RH. Orofacial clefts and maternal anticonvulsant use. Reprod Toxicol 1995; 9:97-98.
49. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972; 2:839-43.
50. Duncan S, Mercho S, Lopes-Cendes I, Seni MH, Benjamin A, Dubeau F, Andermann F, Andermann E. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 2001; 42:750-53.
51. Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, Nakane Y, et al.Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33:145-58.
52. Candito M, Naimi M, Boisson C, Rudigoz JC, Gaucherand P, Gueant JL, Luton D, VanObberghen E. Plasma vitamin values and antiepileptic therapy: Case reports of pregnancy outcomes affected by a neural tube defect. Birth Defects Res A Clin Mol Teratol2007; 79:62-64.
53. da Costa M, Rothenberg SP. Purification and characterization of folate binding proteins from rat placenta. Biochim Biophys Acta 1996; 1292:23-30.
54. da Costa M, Sequeira JM, Rothenberg SP, Weedon J. Antibodies to folate receptors impair embryogenesis and fetal development in the rat. Birth Defects Res A Clin Mol Teratol 2003; 67:837-47.
55. Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts JL, Weedon J, Quadros EV. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004; 350:134-42.
56. Sadasivan E, da Costa M, Rothenberg SP, Brink L. Purification, properties, and immunological characterization of folate-binding proteins from human leukemia cells. Biochim Biophys Acta 1987; 925:36-47.
57. Tang LS, Santillano DR, Wlodarczyk BJ, Miranda RC, Finnell RH. Role of Folbp1 in the regional regulation of apoptosis and cell proliferation in the developing neural tube and craniofacies. Am J Med Genet C Semin Med Genet 2005; 135:48-58.
58. Jakubowski H. Pathophysiological consequences of homocysteine excess. JNutr 2006; 136:1741S-49S.
59. Undas A, Perla J, Lacinski M, Trzeciak W, Kazmierski R, Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: Implications for atherosclerosis. Stroke 2004; 35:1299-304.
60. Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RH. Maternal periconcep-tional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 2002; 108:1-6.
61. Shaw GM, Rozen R, Finnell RH, Todoroff K, Lammer EJ. Infant C677T mutation in MTHFR, maternal periconceptional vitamin use, and cleft lip. Am J Med Genet 1998; 80:196-98.
62. Shaw GM, Rozen R, Finnell RH, Wasserman CR, Lammer EJ. Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida. Am J Epidemiol 1998; 148:30-37.
63. Shaw GM, Zhu H, Lammer EJ, Yang W, Finnell RH. Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial and conotruncal heart defects. Am J Epidemiol2003; 158:747-52.
64. Volcik KA, Blanton SH, Kruzel MC, Townsend IT, Tyerman GH, Mier RJ, Northrup H. Testing for genetic associations with the PAX gene family in a spina bifida population. Am J Med Genet 2002; 110:195-202.
65. Volcik KA, Shaw GM, Lammer EJ, Zhu H, Finnell RH. Evaluation of infant methyl-enetetrahydrofolate reductase genotype, maternal vitamin use, and risk of high versus low level spina bifida defects. Birth Defects Res Part A Clin Mol Teratol 2003; 67:154-57.
66. Zhu H, Wicker NJ, Shaw GM, Lammer EJ, Hendricks K, Suarez L, Canfield M, Finnell RH. Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects. Mol Genet Metab 2003; 78:216-21.
67. Shaw GM, Todoroff K, Finnell RH, Lammer EJ, Leclerc D, Gravel RA, Rozen R. Infant methionine synthase variants and risk for spina bifida. JMed Genet 1999; 36:86-87.
68. Shaw GM, Todoroff K, Finnell RH, Rozen R, Lammer EJ. Maternal vitamin use, infant C677T mutation in MTHFR, and isolated cleft palate risk. Am J Med Genet 1999; 85:84-85.
69. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol 2000; 151:862-77.
70. Gaspar DA, Pavanello RC, Zatz M, Passos-Bueno MR, Andre M, Steman S, Wyszynski DF, Matiolli SR. Role of the C677T polymorphism at the MTHFR gene on risk to nonsyndromic cleft lip with/without cleft palate: Results from a case-control study in Brazil. Am J Med Genet 1999; 87:197-99.
71. Mills JL, Kirke PN, Molloy AM, Burke H, Conley MR, Lee YJ, Mayne PD, Weir DG, Scott JM. Methylenetetrahydrofolate reductase thermolabile variant and oral clefts. Am J Med Genet 1999; 86:71-74.
72. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-13.
73. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ. A second common mutation in the methylenetetrahydrofo-late reductase gene: An additional risk factor for neural-tube defects? Am J Hum Genet1998; 62:1044-51.
74. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydro-folate reductase, and plasma homocysteine concentrations. Circulation 1996; 93:7-9.
75. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64:169-72.
76. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, Eckfeldt JH, Rozen R. The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): In vitro expression and association with homocysteine. Atherosclerosis2001; 156:409-15.
77. Boyles AL, Wilcox AJ, Taylor JA, Meyer K, Fredriksen A, Ueland PM, Drevon CA, Vollset SE, Lie RT. Folate and one-carbon metabolism gene polymorphisms and their associations with oral facial clefts. Am J Med Genet A 2008; 146A:440-49.
78. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 1993; 86:703-08.
79. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R, Blom HJ. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346:1070-71.
80. van der Put NM, van den Heuvel LP, Steegers-Theunissen RP, Trijbels FJ, Eskes TK, Mariman EC, den Heyer M, Blom HJ. Decreased methylene tetrahydrofolate reductase activity due to the 677C-->T mutation in families with spina bifida offspring. J Mol Med1996; 74:691-94.
81. Ou CY, Stevenson RE, Brown VK, Schwartz CE, Allen WP, Khoury MJ, Rozen R, Oakley GP Jr, Adams MJ Jr. 5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 1996; 63:610-14.
82. Grandone E, Corrao AM, Colaizzo D, Vecchione G, Di Girgenti C, Paladini D, Sardella L, et al. Homocysteine metabolism in families from southern Italy with neural tube defects: Role of genetic and nutritional determinants. Prenat Diagn 2006; 26:1-5.
83. Felix TM, Leistner S, Giugliani R. Metabolic effects and the methylenetetrahydrofo-late reductase (MTHFR) polymorphism associated with neural tube defects in southern Brazil. Birth Defects Res A Clin Mol Teratol 2004; 70:459-63.
84. De Marco P, Calevo MG, Moroni A, Arata L, Merello E, Finnell RH, Zhu H, Andreussi L, Cama A, Capra V. Study of MTHFR and MS polymorphisms as risk factors for NTD in the Italian population. J Hum Genet 2002; 47:319-24.
85. De Marco P, Calevo MG, Moroni A, Merello E, Raso A, Finnell RH, Zhu H, Andreussi L, Cama A, Capra V. Reduced folate carrier polymorphism (80A-->G) and neural tube defects. Eur J Hum Genet 2003; 11:245-52.
86. Pei L, Zhu H, Ren A, Li Z, Hao L, Finnell RH. Reduced folate carrier gene is a risk factor for neural tube defects in a Chinese population. Birth Defects Res A Clin Mol Teratol2005; 73:430-33.
87. Pei L, Zhu H, Zhu J, Ren A, Finnell RH, Li Z. Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial defects and congenital heart defects in China. Ann Epidemiol 2006; 16:352-56.
88. Shaw GM, Wasserman CR, Murray JC, Lammer EJ. Infant TGF-alpha genotype, orofacial clefts, and maternal periconceptional multivitamin use. Cleft Palate Craniofac J 1998; 35:366-70.
89. Doolin MT, Barbaux S, McDonnell M, Hoess K, Whitehead AS, Mitchell LE. Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am J Hum Genet 2002; 71:1222-26.
90. Mitchell LE. Epidemiology of neural tube defects. Am J Med Genet C Semin Med Genet2005; 135C:88-94.
91. Posey DL, Khoury MJ, Mulinare J, Adams MJ Jr, Ou CY. Is mutated MTHFR a risk factor for neural tube defects? Lancet 1996; 347:686-87.
92. Yates JR, Ferguson-Smith MA, Shenkin A, Guzman-Rodriguez R, White M, Clark BJ. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects? Clin Genet 1987; 31:279-87.
93. Economides DL, Ferguson J, Mackenzie IZ, Darley J, Ware II, Holmes-Siedle M. Folate and vitamin B12 concentrations in maternal and fetal blood, and amniotic fluid in second trimester pregnancies complicated by neural tube defects. Br J Obstet Gynaecol1992; 99:23-25.
94. Mills JL, Tuomilehto J, Yu KF, Colman N, Blaner WS, Koskela P, Rundle WE, Forman M, Toivanen L, Rhoads GG. Maternal vitamin levels during pregnancies producing infants with neural tube defects. J Pediatr 1992; 120:863-71.
95. Molloy AM, Kirke P, Hillary I, Weir DG, Scott JM. Maternal serum folate and vitamin B12 concentrations in pregnancies associated with neural tube defects. Arch Dis Child1985; 60:660-65.
96. van der Put NM, van Straaten HW, Trijbels FJ, Blom HJ. Folate, homocysteine and neural tube defects: An overview. Exp Biol Med (Maywood) 2001; 226:243-70.
97. Wald NJ, Hackshaw AD, Stone R, Sourial NA. Blood folic acid and vitamin B12 in relation to neural tube defects. Br J Obstet Gynaecol 1996; 103:319-24.
98. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003; 66:403-56.
99. Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 1999; 19:91-122.
100. Maddox DM, Manlapat A, Roon P, Prasad P, Ganapathy V, Smith SB. Reduced-folate carrier (RFC) is expressed in placenta and yolk sac, as well as in cells of the developing forebrain, hindbrain, neural tube, craniofacial region, eye, limb buds and heart. BMC Dev Biol 2003; 3:6.
101. Wang Y, Zhao R, Russell RG, Goldman ID. Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochim Biophys Acta 2001; 1513:49-54.
102. Elwood PC. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J Biol Chem 1989; 264:14893-901.
103. Ratnam M, Marquardt H, Duhring JL, Freisheim JH. Homologous membrane folate binding proteins in human placenta: Cloning and sequence of a cDNA. Biochemistry1989; 28:8249-54.
104. Page ST, Owen WC, Price K, Elwood PC. Expression of the human placental folate receptor transcript is regulated in human tissues. Organization and full nucleotide sequence of the gene. JMol Biol 1993; 229:1175-83.
105. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73:2432-43.
106. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006; 127:917-28.
107. Rouault TA. The intestinal heme transporter revealed. Cell 2005; 122:649-51.
108. Gelineau-van Waes J, Aleman F, Maddox J, Bauer L, Wilberding J, Rosenquist T, Finnell R. Folic acid prevents conotruncal malformations in Folbp1 knockout mice: Role of folate in cardiac neural crest cell survival and migration. In: Jansen G, Peters G, eds., Chemistry and Biology of Pteridines and Folates. Heilbronn, Germany: Kluwer Academic Publishers, 2007:483-502.
109. Spiegelstein O, Gould A, Wlodarczyk B, Tsie M, Lu X, Le C, Troen A, et al.Developmental consequences of in utero sodium arsenate exposure in mice with folate transport deficiencies. Toxicol Appl Pharmacol 2005; 203:18-26.
110. Zhu H, Wlodarczyk BJ, Scott M, Yu W, Merriweather M, Gelineau-van Waes J, Schwartz RJ, Finnell RH. Cardiovascular abnormalities in Folr1 knockout mice and folate rescue. Birth Defects Res A Clin Mol Teratol 2007; 79:257-68.
111. Ma DW, Finnell RH, Davidson LA, Callaway ES, Spiegelstein O, Piedrahita JA, Salbaum JM, et al. Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Res 2005; 65:887-97.
112. Wlodarczyk B, Spiegelstein O, Gelineau-van Waes J, Vorce RL, Lu X, Le CX, Finnell RH. Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice. Toxicol Appl Pharmacol 2001; 177:238-46.
113. Spiegelstein O, Merriweather MY, Wicker NJ, Finnell RH. Valproate-induced neural tube defects in folate-binding protein-2 (Folbp2) knockout mice. Birth Defects Res A Clin Mol Teratol 2003; 67:974-78.
114. Zhao R, Russell RG, Wang Y, Liu L, Gao F, Kneitz B, Edelmann W, Goldman ID. Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem2001; 276:10224-28.
115. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, Chen MF, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomo-cysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001; 10:433-43.
116. Finnell RH, Wlodarczyk BC, Craig JC, Piedrahita JA, Bennett GD. Strain-dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model. Am J Med Genet 1997; 70:303-11.
117. Bower C, Stanley FJ, Croft M, de Klerk N, Davis RE, Nicol DJ. Absorption of pteroylpo-lyglutamates in mothers of infants with neural tube defects. Br J Nutr 1993; 69:827-34.
118. Bower C, Stanley FJ, Nicol DJ. Maternal folate status and the risk for neural tube defects. The role of dietary folate. Ann N YAcad Sci 1993; 678:146-55.
119. Gardiki-Kouidou P, Seller MJ. Amniotic fluid folate, vitamin B12 and transcobalamins in neural tube defects. Clin Genet 1988; 33:441-48.
120. Lucock MD, Wild J, Schorah CJ, Levene MI, Hartley R. The methylfolate axis in neural tube defects: In vitro characterisation and clinical investigation. Biochem Med Metab Biol 1994; 52:101-14.
121. Weekes EW, Tamura T, Davis RO, Birch R, Vaughn WH, Franklin JC, Barganier C, Cosper P, Finley SC, Finley WH. Nutrient levels in amniotic fluid from women with normal and neural tube defect pregnancies. Biol Neonate 1992; 61:226-31.
122. Wild J, Schorah CJ, Sheldon TA, Smithells RW. Investigation of factors influencing folate status in women who have had a neural tube defect-affected infant. Br J Obstet Gynaecol 1993; 100:546-49.
123. Schorah CJ, Habibzadeh N, Wild J, Smithells RW, Seller MJ. Possible abnormalities of folate and vitamin B12 metabolism associated with neural tube defects. Ann N Y Acad Sci 1993; 678:81-91.
124. Gelineau-van Waes J, Maddox JR, Smith LM, van Waes M, Wilberding J, Eudy JD, Bauer LK, Finnell RH. Microarray analysis of E9.5 reduced folate carrier (RFC1; Slc19a1) knockout embryos reveals altered expression of genes in the cubilin-megalin multiligand endocytic receptor complex. BMC Genomics 2008; 9:156.
125. Taparia S, Gelineau-van Waes J, Rosenquist TH, Finnell RH. Importance of folate-homocysteine homeostasis during early embryonic development. Clin Chem Lab Med2007; 45:1717-27.